---
document_datetime: 2025-11-23 13:10:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/desloratadine-teva.html
document_name: desloratadine-teva.html
version: success
processing_time: 0.1271625
conversion_datetime: 2025-12-26 12:35:13.476376
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Desloratadine Teva

[RSS](/en/individual-human-medicine.xml/67084)

##### Authorised

This medicine is authorised for use in the European Union

desloratadine

Medicine

Human

Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Desloratadine Teva](#more-information-on-desloratadine-teva-1530)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Desloratadine Teva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Desloratadine Teva.

Expand section

Collapse section

## What is Desloratadine Teva?

Desloratadine Teva is a medicine containing the active substance desloratadine. It is available as tablets (5 mg).

Desloratadine Teva is a 'generic medicine'. This means that Desloratadine Teva is similar to a 'reference medicine' already authorised in the European Union (EU) called Aerius.

## What is Desloratadine Teva used for?

Desloratadine Teva is used to relieve the symptoms of allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) or urticaria (a skin condition caused by an allergy, with symptoms including itching and hives).

The medicine can only be obtained with a prescription.

## How is Desloratadine Teva used?

The recommended dose for adults and adolescents (12 years of age and over) is one tablet once a day.

## How does Desloratadine Teva work?

The active substance in Desloratadine Teva, desloratadine, is an antihistamine. It works by blocking the receptors on which histamine, a substance in the body that causes allergic symptoms, normally fixes itself. When the receptors are blocked, histamine cannot have its effect, and this leads to a decrease in the symptoms of allergy.

## How has Desloratadine Teva been studied?

Because Desloratadine Teva is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Aerius. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefits and risks of Desloratadine Teva?

Because Desloratadine Teva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why has Desloratadine Teva been approved?

The CHMP concluded that, in accordance with EU requirements, Desloratadine Teva has been shown to have comparable quality and to be bioequivalent to Aerius. Therefore, the CHMP's view was that, as for Aerius, the benefit outweighs the identified risk. The Committee recommended that Desloratadine Teva be given marketing authorisation.

## Other information about Desloratadine Teva

The European Commission granted a marketing authorisation valid throughout the European Union for Desloratadine Teva on 24 November 2011.

For more information about treatment with Desloratadine Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Desloratadine Teva : EPAR - Summary for the public

Reference Number: EMA/CHMP/654268/2011

English (EN) (53.75 KB - PDF)

**First published:** 08/12/2011

**Last updated:** 08/12/2011

[View](/en/documents/overview/desloratadine-teva-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-912)

български (BG) (89.32 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

08/12/2011

[View](/bg/documents/overview/desloratadine-teva-epar-summary-public_bg.pdf)

español (ES) (54.7 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

08/12/2011

[View](/es/documents/overview/desloratadine-teva-epar-summary-public_es.pdf)

čeština (CS) (80.14 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

08/12/2011

[View](/cs/documents/overview/desloratadine-teva-epar-summary-public_cs.pdf)

dansk (DA) (54.15 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

08/12/2011

[View](/da/documents/overview/desloratadine-teva-epar-summary-public_da.pdf)

Deutsch (DE) (116.77 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

08/12/2011

[View](/de/documents/overview/desloratadine-teva-epar-summary-public_de.pdf)

eesti keel (ET) (53.42 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

08/12/2011

[View](/et/documents/overview/desloratadine-teva-epar-summary-public_et.pdf)

ελληνικά (EL) (150.47 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

08/12/2011

[View](/el/documents/overview/desloratadine-teva-epar-summary-public_el.pdf)

français (FR) (54.42 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

08/12/2011

[View](/fr/documents/overview/desloratadine-teva-epar-summary-public_fr.pdf)

italiano (IT) (56.31 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

08/12/2011

[View](/it/documents/overview/desloratadine-teva-epar-summary-public_it.pdf)

latviešu valoda (LV) (80.02 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

08/12/2011

[View](/lv/documents/overview/desloratadine-teva-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (78.46 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

08/12/2011

[View](/lt/documents/overview/desloratadine-teva-epar-summary-public_lt.pdf)

magyar (HU) (135.08 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

08/12/2011

[View](/hu/documents/overview/desloratadine-teva-epar-summary-public_hu.pdf)

Malti (MT) (80.63 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

08/12/2011

[View](/mt/documents/overview/desloratadine-teva-epar-summary-public_mt.pdf)

Nederlands (NL) (54.11 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

08/12/2011

[View](/nl/documents/overview/desloratadine-teva-epar-summary-public_nl.pdf)

polski (PL) (81.16 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

08/12/2011

[View](/pl/documents/overview/desloratadine-teva-epar-summary-public_pl.pdf)

português (PT) (70.33 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

08/12/2011

[View](/pt/documents/overview/desloratadine-teva-epar-summary-public_pt.pdf)

română (RO) (78.06 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

08/12/2011

[View](/ro/documents/overview/desloratadine-teva-epar-summary-public_ro.pdf)

slovenčina (SK) (76.76 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

08/12/2011

[View](/sk/documents/overview/desloratadine-teva-epar-summary-public_sk.pdf)

slovenščina (SL) (75.98 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

08/12/2011

[View](/sl/documents/overview/desloratadine-teva-epar-summary-public_sl.pdf)

Suomi (FI) (53.59 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

08/12/2011

[View](/fi/documents/overview/desloratadine-teva-epar-summary-public_fi.pdf)

svenska (SV) (54.4 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

08/12/2011

[View](/sv/documents/overview/desloratadine-teva-epar-summary-public_sv.pdf)

## Product information

Desloratadine Teva : EPAR - Product information

English (EN) (190.92 KB - PDF)

**First published:** 08/12/2011

**Last updated:** 09/06/2022

[View](/en/documents/product-information/desloratadine-teva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-421)

български (BG) (293.11 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

09/06/2022

[View](/bg/documents/product-information/desloratadine-teva-epar-product-information_bg.pdf)

español (ES) (315.57 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

09/06/2022

[View](/es/documents/product-information/desloratadine-teva-epar-product-information_es.pdf)

čeština (CS) (264.06 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

09/06/2022

[View](/cs/documents/product-information/desloratadine-teva-epar-product-information_cs.pdf)

dansk (DA) (316.8 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

09/06/2022

[View](/da/documents/product-information/desloratadine-teva-epar-product-information_da.pdf)

Deutsch (DE) (341.36 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

09/06/2022

[View](/de/documents/product-information/desloratadine-teva-epar-product-information_de.pdf)

eesti keel (ET) (315.84 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

09/06/2022

[View](/et/documents/product-information/desloratadine-teva-epar-product-information_et.pdf)

ελληνικά (EL) (406.44 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

09/06/2022

[View](/el/documents/product-information/desloratadine-teva-epar-product-information_el.pdf)

français (FR) (205.22 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

09/06/2022

[View](/fr/documents/product-information/desloratadine-teva-epar-product-information_fr.pdf)

hrvatski (HR) (344.48 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

09/06/2022

[View](/hr/documents/product-information/desloratadine-teva-epar-product-information_hr.pdf)

íslenska (IS) (313.99 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

09/06/2022

[View](/is/documents/product-information/desloratadine-teva-epar-product-information_is.pdf)

italiano (IT) (330.64 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

09/06/2022

[View](/it/documents/product-information/desloratadine-teva-epar-product-information_it.pdf)

latviešu valoda (LV) (498.75 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

09/06/2022

[View](/lv/documents/product-information/desloratadine-teva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (378.02 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

09/06/2022

[View](/lt/documents/product-information/desloratadine-teva-epar-product-information_lt.pdf)

magyar (HU) (375.71 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

09/06/2022

[View](/hu/documents/product-information/desloratadine-teva-epar-product-information_hu.pdf)

Malti (MT) (374.91 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

09/06/2022

[View](/mt/documents/product-information/desloratadine-teva-epar-product-information_mt.pdf)

Nederlands (NL) (313.96 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

09/06/2022

[View](/nl/documents/product-information/desloratadine-teva-epar-product-information_nl.pdf)

norsk (NO) (315.7 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

09/06/2022

[View](/no/documents/product-information/desloratadine-teva-epar-product-information_no.pdf)

polski (PL) (269.39 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

09/06/2022

[View](/pl/documents/product-information/desloratadine-teva-epar-product-information_pl.pdf)

português (PT) (311.14 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

09/06/2022

[View](/pt/documents/product-information/desloratadine-teva-epar-product-information_pt.pdf)

română (RO) (250.92 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

09/06/2022

[View](/ro/documents/product-information/desloratadine-teva-epar-product-information_ro.pdf)

slovenčina (SK) (240.31 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

09/06/2022

[View](/sk/documents/product-information/desloratadine-teva-epar-product-information_sk.pdf)

slovenščina (SL) (242.64 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

09/06/2022

[View](/sl/documents/product-information/desloratadine-teva-epar-product-information_sl.pdf)

Suomi (FI) (397.9 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

09/06/2022

[View](/fi/documents/product-information/desloratadine-teva-epar-product-information_fi.pdf)

svenska (SV) (314.7 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

09/06/2022

[View](/sv/documents/product-information/desloratadine-teva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00000962/202107 30/05/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Desloratadine Teva : EPAR - All Authorised presentations

English (EN) (13.86 KB - PDF)

**First published:** 08/12/2011

**Last updated:** 19/10/2015

[View](/en/documents/all-authorised-presentations/desloratadine-teva-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-484)

български (BG) (14.46 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

19/10/2015

[View](/bg/documents/all-authorised-presentations/desloratadine-teva-epar-all-authorised-presentations_bg.pdf)

español (ES) (12.9 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

19/10/2015

[View](/es/documents/all-authorised-presentations/desloratadine-teva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (21.46 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

19/10/2015

[View](/cs/documents/all-authorised-presentations/desloratadine-teva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (13.36 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

19/10/2015

[View](/da/documents/all-authorised-presentations/desloratadine-teva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (14.13 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

19/10/2015

[View](/de/documents/all-authorised-presentations/desloratadine-teva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (28.11 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

19/10/2015

[View](/et/documents/all-authorised-presentations/desloratadine-teva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (32.88 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

19/10/2015

[View](/el/documents/all-authorised-presentations/desloratadine-teva-epar-all-authorised-presentations_el.pdf)

français (FR) (12.29 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

19/10/2015

[View](/fr/documents/all-authorised-presentations/desloratadine-teva-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (27.82 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

19/10/2015

[View](/hr/documents/all-authorised-presentations/desloratadine-teva-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (14.31 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

19/10/2015

[View](/is/documents/all-authorised-presentations/desloratadine-teva-epar-all-authorised-presentations_is.pdf)

italiano (IT) (15.3 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

19/10/2015

[View](/it/documents/all-authorised-presentations/desloratadine-teva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (30.5 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

19/10/2015

[View](/lv/documents/all-authorised-presentations/desloratadine-teva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (34.52 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

19/10/2015

[View](/lt/documents/all-authorised-presentations/desloratadine-teva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (26.27 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

19/10/2015

[View](/hu/documents/all-authorised-presentations/desloratadine-teva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (32.03 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

19/10/2015

[View](/mt/documents/all-authorised-presentations/desloratadine-teva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (15.78 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

19/10/2015

[View](/nl/documents/all-authorised-presentations/desloratadine-teva-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (14.13 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

19/10/2015

[View](/no/documents/all-authorised-presentations/desloratadine-teva-epar-all-authorised-presentations_no.pdf)

polski (PL) (36.96 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

19/10/2015

[View](/pl/documents/all-authorised-presentations/desloratadine-teva-epar-all-authorised-presentations_pl.pdf)

português (PT) (13.56 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

19/10/2015

[View](/pt/documents/all-authorised-presentations/desloratadine-teva-epar-all-authorised-presentations_pt.pdf)

română (RO) (29.41 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

19/10/2015

[View](/ro/documents/all-authorised-presentations/desloratadine-teva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (19.15 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

19/10/2015

[View](/sk/documents/all-authorised-presentations/desloratadine-teva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (27.14 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

19/10/2015

[View](/sl/documents/all-authorised-presentations/desloratadine-teva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (12.52 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

19/10/2015

[View](/fi/documents/all-authorised-presentations/desloratadine-teva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (14.22 KB - PDF)

**First published:**

08/12/2011

**Last updated:**

19/10/2015

[View](/sv/documents/all-authorised-presentations/desloratadine-teva-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Desloratadine Teva Active substance desloratadine International non-proprietary name (INN) or common name desloratadine Therapeutic area (MeSH)

- Rhinitis, Allergic, Perennial
- Rhinitis, Allergic, Seasonal

Anatomical therapeutic chemical (ATC) code R06AX27

### Pharmacotherapeutic group

Antihistamines for systemic use

### Therapeutic indication

Desloratadine Teva is indicated for the relief of symptoms associated with:

- allergic rhinitis;
- urticaria.

## Authorisation details

EMA product number EMEA/H/C/002419

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva B.V

Swensweg 5

Opinion adopted 22/09/2011 Marketing authorisation issued 24/11/2011 Revision 18

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Desloratadine Teva : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (168.26 KB - PDF)

**First published:** 11/07/2012

**Last updated:** 09/06/2022

[View](/en/documents/procedural-steps-after/desloratadine-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Desloratadine Teva-H-C-PSUSA-00000962-202107 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/567651/2022

English (EN) (128.84 KB - PDF)

**First published:** 09/06/2022

[View](/en/documents/scientific-conclusion/desloratadine-teva-h-c-psusa-00000962-202107-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Desloratadine Teva-H-C-PSUSA-00000962-201607 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/333803/2017

English (EN) (101.36 KB - PDF)

**First published:** 07/06/2017

**Last updated:** 07/06/2017

[View](/en/documents/scientific-conclusion/desloratadine-teva-h-c-psusa-00000962-201607-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Desloratadine Teva : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/654268/2011

English (EN) (235.18 KB - PDF)

**First published:** 08/12/2011

**Last updated:** 08/12/2011

[View](/en/documents/assessment-report/desloratadine-teva-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Desloratadine Teva

Adopted

Reference Number: EMA/CHMP/749646/2011

English (EN) (53.03 KB - PDF)

**First published:** 23/09/2011

**Last updated:** 23/09/2011

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-desloratadine-teva_en.pdf)

#### More information on Desloratadine Teva

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-44)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 09/06/2022

## Share this page

[Back to top](#main-content)